128 related articles for article (PubMed ID: 1750507)
21. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
Gulyás M; Hjerpe A
J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
[TBL] [Abstract][Full Text] [Related]
22. Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed hairless mice: kinetics of induction, effects of DNA repair deficiency, and p53 heterozygosity.
Rebel H; Mosnier LO; Berg RJ; Westerman-de Vries A; van Steeg H; van Kranen HJ; de Gruijl FR
Cancer Res; 2001 Feb; 61(3):977-83. PubMed ID: 11221893
[TBL] [Abstract][Full Text] [Related]
23. Activation of Akt and mTOR in CD34+/K15+ keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis.
Affara NI; Trempus CS; Schanbacher BL; Pei P; Mallery SR; Bauer JA; Robertson FM
Anticancer Res; 2006; 26(4B):2805-20. PubMed ID: 16886599
[TBL] [Abstract][Full Text] [Related]
24. A novel laminin-binding form of syndecan-1 (cell surface proteoglycan) produced by syndecan-1 cDNA-transfected NIH-3T3 cells.
Salmivirta M; Mali M; Heino J; Hermonen J; Jalkanen M
Exp Cell Res; 1994 Nov; 215(1):180-8. PubMed ID: 7957667
[TBL] [Abstract][Full Text] [Related]
25. Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements.
Brockstedt U; Dobra K; Nurminen M; Hjerpe A
Exp Cell Res; 2002 Apr; 274(2):235-45. PubMed ID: 11900484
[TBL] [Abstract][Full Text] [Related]
26. Membrane-anchored proteoglycans of mouse macrophages: P388D1 cells express a syndecan-4-like heparan sulfate proteoglycan and a distinct chondroitin sulfate form.
Yeaman C; Rapraeger AC
J Cell Physiol; 1993 Nov; 157(2):413-25. PubMed ID: 8227171
[TBL] [Abstract][Full Text] [Related]
27. Toxicology and Carcinogenesis Studies of 4-Vinyl-1-cyclohexene Diepoxide (CAS No. 106-87-6) in F344/N Rats and B6C3F1 Mice (Dermal Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1989 Nov; 362():1-249. PubMed ID: 12695779
[TBL] [Abstract][Full Text] [Related]
28. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.
Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Takamori K; Igawa K; Yoshida M; Fukuyama H; Takahashi T; Sakoda S
J Oral Pathol Med; 2006 May; 35(5):301-6. PubMed ID: 16630294
[TBL] [Abstract][Full Text] [Related]
29. Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis.
La E; Muga SJ; Locniskar MF; Fischer SM
Mol Carcinog; 1999 Apr; 24(4):276-86. PubMed ID: 10326864
[TBL] [Abstract][Full Text] [Related]
30. Syndecan-1 in B lymphoid malignancies.
Sanderson RD; Børset M
Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737
[TBL] [Abstract][Full Text] [Related]
31. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium.
Soukka T; Pohjola J; Inki P; Happonen RP
J Oral Pathol Med; 2000 Aug; 29(7):308-13. PubMed ID: 10947246
[TBL] [Abstract][Full Text] [Related]
32. Life history and histopathology of ultraviolet light-induced skin tumors.
Stenbäck F
Natl Cancer Inst Monogr; 1978 Dec; (50):57-70. PubMed ID: 112477
[TBL] [Abstract][Full Text] [Related]
33. The distribution of syndecan during murine secondary palate morphogenesis.
Brinkley L; Morris-Wiman J; Bernfield M
J Craniofac Genet Dev Biol; 1992; 12(2):82-9. PubMed ID: 1613077
[TBL] [Abstract][Full Text] [Related]
34. The expression of syndecan-1 is preferentially reduced compared with that of E-cadherin in acantholytic squamous cell carcinoma.
Bayer-Garner IB; Smoller BR
J Cutan Pathol; 2001 Feb; 28(2):83-9. PubMed ID: 11168756
[TBL] [Abstract][Full Text] [Related]
35. Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinoma.
Bayer-Garner IB; Sanderson RD; Smoller BR
J Cutan Pathol; 1999 Sep; 26(8):386-90. PubMed ID: 10551410
[TBL] [Abstract][Full Text] [Related]
36. Epidermal abnormalities and increased malignancy of skin tumors in human epidermal keratin 8-expressing transgenic mice.
Casanova ML; Bravo A; Martínez-Palacio J; Fernández-Aceñero MJ; Villanueva C; Larcher F; Conti CJ; Jorcano JL
FASEB J; 2004 Oct; 18(13):1556-8. PubMed ID: 15319370
[TBL] [Abstract][Full Text] [Related]
37. The role of syndecan-1 in malignancies.
Inki P; Jalkanen M
Ann Med; 1996 Feb; 28(1):63-7. PubMed ID: 8932508
[TBL] [Abstract][Full Text] [Related]
38. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer.
Lundin M; Nordling S; Lundin J; Isola J; Wiksten JP; Haglund C
Oncology; 2005; 68(4-6):306-13. PubMed ID: 16020957
[TBL] [Abstract][Full Text] [Related]
39. Dermatofibroma: upregulation of syndecan-1 expression in mesenchymal tissue.
Sellheyer K; Smoller BR
Am J Dermatopathol; 2003 Oct; 25(5):392-8. PubMed ID: 14501288
[TBL] [Abstract][Full Text] [Related]
40. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma.
Bayer-Garner IB; Dilday B; Sanderson RD; Smoller BR
Am J Dermatopathol; 2000 Apr; 22(2):119-22. PubMed ID: 10770430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
